Daclatasvir (Daklinza) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults
U.S. Food and Drug Administration approved Daclatasvir for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015. Daclatasvir is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
Read U.S FDA Announcement
Daclatasvir inhibits the HCV non-structural protein NS5A. Research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.
Daclatasvir (Daklinza) was developed by Bristol-Myers Squibb
Presently in India Hetero has launched Generic Version of Daclatasvir, DaclaHep. Please click here to know more.
Daclahep is generic Version of Daklinza (Daclatasvir)
PACK : 28 TABLETS BOTTLE
HETERO HEALTHCARE INDIA.
Pack & Strength
Each film-coated tablet contains Daclatasvir dihydrochloride equivalent to 30 mg or 60 mg Daclatasvir.
Daclatasvir (Daklinza) carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia).
Daclatasvir is to be taken strictly under Medical Supervision of Hepatologist /Gastroenterologist/HCV only